LIFECORE BIOMEDICAL, INC. Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31)
LIFECORE BIOMEDICAL, INC. (LFCR) had Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) of -$3.93 million as of 2012-04-23, per its 10-K filed 2013-08-07.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionContingentConsiderationAtFairValue · last filed 2013-08-07
- 2012-04-23: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) -$3.93M; Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) as first filed -$3.93M.
| Period end | Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) | Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) as first filed |
|---|---|---|
| 2012-04-23 | -$3.93M 10-K · filed 2013-08-07 | -$3.93M 10-Q · filed 2012-10-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |